Chimeric antigen receptors (CARs) from bench-to-bedside.
Chimeric antigen receptors (CARs) combine the antigen specificity of an antibody with the biologic properties of T lymphocytes. While the concept has been developed more than 20 years ago, only in recent years the clinical application of this approach has produced remarkable objective clinical responses. In this brief review, we outline some specific aspects that have led to antitumor responses in cancer patients.
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, TX 77030, USA; Department of Pediatrics, Texas Children's Hospital, Houston, TX 77030, USA.
Barbara
B
Savoldo
Gianpietro
G
Dotti
D000818:Animals; D000906:Antibodies / Q000235:genetics; D019496:Cancer Vaccines; D015316:Genetic Therapy; D006801:Humans; D016219:Immunotherapy, Adoptive; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011946:Receptors, Antigen / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology*; D013601:T-Lymphocytes / Q000502:physiology*
D000906:Antibodies; D019496:Cancer Vaccines; D011946:Receptors, Antigen; D011993:Recombinant Fusion Proteins
Chimeric antigen receptor; Gene therapy; T cell immunotherapy